

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **Voluntary Announcement Cooperation Framework Agreement with Zhejiang Apeloa**

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors (the “Board”) of the Company is pleased to announce that United Laboratories (Inner Mongolia) Limited (聯邦制藥(內蒙古)有限公司) (“United Laboratories (Inner Mongolia)”), a wholly-owned subsidiary of the Company, and 浙江普洛生物科技股份有限公司 (Zhejiang Apeloa Biotechnology Co., Ltd.) (“Zhejiang Apeloa”) have jointly signed a cooperation framework agreement (the “Cooperation Framework Agreement”) in relation to veterinary medicine. Pursuant to the Cooperation Framework Agreement, United Laboratories (Inner Mongolia) and Zhejiang Apeloa will establish an operating joint venture (the “Joint Venture”) with a registered capital of RMB300 million by way of contribution in cash. United Laboratories (Inner Mongolia) will hold 49% equity interest in the Joint Venture.

Zhejiang Apeloa is a biopharmaceutical company specializing in the research, development and production of fermented APIs, and is a wholly-owned subsidiary of Apeloa Pharmaceutical Co., Ltd. (普洛藥業股份有限公司) which is listed on Shenzhen Stock Exchange (stock code: SZ000739).

In view of the advantageous resources and scale advantage of established corporate public resources of United Laboratories (Inner Mongolia), as well as the market resources and technological competitiveness of Zhejiang Apeloa accumulated in biofermented veterinary antibiotics, both parties will make use of their respective strengths to develop strategic cooperation in the field of veterinary medicine and strive to establish a comprehensive competitiveness in the veterinary medicine in terms of technology, production and market. The preliminary cooperative project of the Joint Venture involves four veterinary antibiotic products. Production will be managed by both parties respectively, and marketing of the products will be responsible by a team assigned to the Joint Venture by Zhejiang Apeloa.

This cooperation is based on the strengths of both parties and their cooperation and trust over the years. The aim is to further strengthen the market dominance of relevant veterinary medicine products by leveraging the technological, market and other resources of both parties, and to jointly promote synergistic business development in the field of veterinary medicine.

A formal agreement in relation to the Joint Venture will be signed in due course.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 27 July 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.